reviewJournal of Hematology & OncologyJul 16, 2022GOLD OA

Exploring immunotherapy in colorectal cancer

JWJunyong WengSLShanbao LiZZZhonglin ZhuQLQi LiuRZRuoxin Zhang

Fudan University Shanghai Cancer Center · Shanghai Jiao Tong University · +1 more institution

PubMed
Indexed incrossrefdoajpubmed

Abstract

Chemotherapy combined with or without targeted therapy is the fundamental treatment for metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs and the biological characteristics of the tumor cells, it is difficult to make breakthroughs in traditional strategies. The immune checkpoint blockades (ICB) therapy has made significant progress in the treatment of advanced malignant tumors, and patients who benefit from this therapy may obtain a long-lasting response. Unfortunately, immunotherapy is only effective in a limited number of patients with microsatellite instability-high (MSI-H), and segment initial responders can subsequently develop acquired resistance. From September 4,…

Citation impact

334
total citations
FWCI
31.20
Percentile
100%
References
226
Citations per year

Authors

7

Topics & keywords

Topics
Keywords
  • Medicine
  • Pembrolizumab
  • Colorectal cancer
  • Immunotherapy
  • Oncology
  • Microsatellite instability
  • Internal medicine
  • Clinical trial
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding